Immunoglobulin Reconstitution And Survival Analysis Of Multiple Myeloma Patients After Autologous Hematopoietic Stem Cell Transplantation

Objective:To investigate whether the recovery of polyclonal immunoglubulin after autologous hematopoietic stem cell transplantation(ASCT)is of prognostic value in a cohort of patients with multiple myeloma(MM).Methods:Clinical data of 40 MM patients after ASCT were analyzed retrospectively,and polyclonal immunoglobulin recovery and survival prognosis differences were analyzed at different time nodes.Results:Hematopoietic reconstruction was obtained in 39 patients,and one patient had secondary plasmacellular leukemia 2 months after ASCT.As complete remission(CR),partial remission and very good partial remission(VGPR)were defined as overall response rate(ORR),the rate was 92.3% after transplantation,higher than that before treatment(89.7%),but there was no significant differenvce.Polyclonal immunoglubulin recovery at 3 months in 7 of 39 patients without relapse and death(17.9%),15 of 36(41.7%)at 6 months,and 18 in 30 patients without recurrence and death(60%).And the earlier the immunoglobulin recovery time within 1 year,the longer the progression-free survival(PFS)is statistically significant(P<0.05).COX multivariate regression revealed1 year immunoglobulin recovery as an independent prognostic factor for progression-free survival(PFS)(P <0.05)and overall survival(OS)(P<0.05).mSMART3.0 stratification is also an independent prognostic factor for PFS and OS,with no significant statistical differences in PFS and OS across ISS stages,demonstrating that risk stratification had greater prognostic significance.Conclusion:Immunoglobulin recovery and mSMART3.0 risk stratification 1 year after ASCT are independent prognostic factors for PFS and OS.